Future Outlook of the HERG Screening Market: Growth, Trends, and Emerging Opportunities Explored
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Expected Growth Rate of the HERG Screening Market Based on Industry Projections?
Recent years have seen a quick expansion in the size of the HERG screening market. Projected to rise from $1.62 billion in 2024 to $1.84 billion in 2025, this market demonstrates a compound annual growth rate (CAGR) of 13.9%. The growth observed during the historic period is largely due to the rise in pharmaceutical advancements, regulatory standards, increased consciousness concerning heart health, and a growing occurrence of heart-related ailments.
Over the next few years, a swift expansion is anticipated for the HERG screening market, predicted to reach a worth of $2.9 billion by 2029, coming to represent a compound annual growth rate (CAGR) of 12.0%. The projected growth in this period can largely be linked to the increasing embrace of personalized medicine, a surge in drug development activities being outsourced, the rise of emerging research markets, as well as a heightened emphasis on non-cardiac safety evaluations. Key trends in this forecast period comprise improvements in in vitro models, concerted efforts in combining genomic and proteomic data, progress in computational methodologies, a focus on the safety of pediatric drugs, and partnerships encouraging the standardization and sharing of data.
What Are the Primary Drivers Supporting the Growth of the herg screening Market?
The HERG screening market’s exponential growth is largely attributed to the increasing number of patients suffering from heart disorders. These disorders, also commonly referred to as cardiovascular diseases, encompass an array of conditions impacting the heart and blood vessels. Such conditions contribute to impaired heart functioning and pose serious health risks. Risk factors leading to these disorders involve unhealthy lifestyle choices, an aging population, genetic predispositions, diabetes, and metabolic syndrome. By employing HERG screening, potential drug candidates can be identified to prevent severe cardiac occurrences that could result in fatal cardiac arrhythmias, particularly torsade de pointes (TdP), thereby enhancing the patient’s health prognosis. For example, as per a May 2023 report compiled by the Centers for Disease Control and Prevention, a public health entity based in the US, cardiovascular diseases affected 1 in 20 adults aged 20 and over, with about 695,000 people grappling with these diseases, leading to 375,476 fatalities. Also, a report furnished by the Office for National Statistics, a governmental entity based in the UK, showed that heart attacks claimed the lives of 20,061 individuals in March 2022, marking an annual increase. Consequently, the growth of the HERG screening market is being propelled by the escalated numbers of patients diagnosed with heart disorders.
Explore Comprehensive Insights Into The Global HERG Screening Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp
What Companies Are At the Forefront of Innovation in the HERG Screening Market?
Major companies operating in the HERG screening market are:
• Eurofins-Cerep SA._x000D_
• Aviva Biosciences Inc._x000D_
• AstraZeneca Public Limited Company_x000D_
• Merck KGaA_x000D_
• Charles River Laboratories Inc._x000D_
How Are Emerging Trends in Consumer Behavior Affecting the HERG Screening Market?
Leading firms in the HERG screening market are focusing on the integration of innovative advanced solutions like GLP-certified HERG screening services to boost cardiac safety evaluations during the drug development process. This service entails the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) through the traditional whole-cell patch-clamp method. This method ensures the screening aligns with regulatory protocols such as ICH S7A and ICH S7B which are crucial for safety pharmacology studies during the drug development stage. An illustration of this is when Metrion Biosciences Ltd., a pharmaceutical company based in the UK, introduced its good laboratory practice (GLP)-certified hERG screening service in August 2023. The aim of this service is to amplify Metrion’s assistance for the development of small molecule therapeutics and supplement the company’s existing cardiac safety services. Furthermore, this service employs the traditional whole-cell patch-clamp method to determine potential cardiac risks before initiating Phase 1 human clinical trials, offers regulatory advice for safety pharmacology studies in drug development, as well as providing clients with quality biology services for ion channel targets.
Secure Your Global HERG Screening Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report
How Are Market Segments in the HERG Screening Industry Positioned for Long-Term Growth?
The HERG screening market covered in this report is segmented –
1) By Type: Gene KCNH2, Mutant KCNH2
2) By Ion Channel: Voltage-Gated, Ligand Gated
3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications
Subsegmeents:
1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2
2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations
What Regions Are Propelling Growth in the HERG Screening Industry?
North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does the Definition of the HERG Screening Market Include?
Human Ether-à-go-go-related gene (HERG) screening refers to the process of assessing the potential cardiotoxicity of a drug or compound. HERG screening is an important component of preclinical safety assessment in drug discovery and development, ensuring the safety and efficacy of novel therapeutic agents.
Browse Through More Similar Reports By The Business Research Company:
Cellular Health Screening Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report
Crushing, Screening, And Mineral Processing Equipment Global Market Report 2024
Blood Screening Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
